Testosterone Cypionate / Testosterone Propionate Injection
Overview of Testosterone Cypionate / Testosterone Propionate Injection
Dosage Strength
Testosterone Cypionate / Testosterone Propionate 160/40 mg/mL 5 mL Vial (Grapeseed Oil)General Information
The first anabolic steroid that was effectively produced was testosterone. A fast-acting, short-ester, oil-based testosterone injectable molecule called testosterone propionate is frequently administered to treat male hypogonadism, or low testosterone levels, and its numerous symptoms.
The purpose of testosterone propionate, which slows the release of synthetic testosterone into the bloodstream, was first described in 1935 to improve the therapeutic utility of the substance. Two years later, Schering AG in Germany made it available for therapeutic usage. It was sold under the trade name Testoviron and combined with testosterone enanthate. Prior to 1960, this type of testosterone dominated the market for prescription medications in the United States and was also the first one that was commercially available there.
The main androgen in the body is testosterone. Species of cells in the testis, ovary, and adrenal cortex produce endogenous testosterone. In the treatment of either congenital or acquired hypogonadism, testosterone is employed. The best exogenous androgen for the palliative therapy of breast cancer in postmenopausal women is testosterone. In 1938, testosterone was in use, and the FDA gave its approval in 1939. Since they have been used illegally, anabolic steroids, which are testosterone derivatives, are now considered controlled substances. In 1991, testosterone, along with a number of anabolic steroids, was designated as a restricted substance. Parenterally given dosages of both standard and delayed-release (depot) testosterone are available. The FDA initially approved testosterone transdermal patches (Androderm) in September 1995; today, there are numerous transdermal brands, forms, and products available, including implants, gels, and topical treatments. In July 2003, the FDA authorized the Striant testosterone buccal system. This mucoadhesive device clings to the buccal mucosa and offers a controlled and sustained release of testosterone. The FDA authorized an intranasal gel formulation in May 2014. (Natesto). The use of a transdermal patch (Intrinsa) for female hormone replacement is being studied; daily dosages are substantially lower for female users than for male users. The FDA decided to postpone the approval of the Intrinsa women’s testosterone patch in late 2004 and has since demanded more safety information, particularly in regards to cardiovascular and breast health.
The propionate ester is a type of chemical molecule that reacts with water to form alcohols and organic or inorganic acids. The majority of esters are made from carboxylic acids, and one or more esters are frequently supplied along with injectable testosterone. The testosterone molecule has an ester added to it, which affects how soluble it is after it enters the bloodstream. A large/long ester will have a longer half-life; the longer the carbon chain, the longer the ester, and the less soluble the drug. In contrast, short carbon chains, such as the propionate ester, act quickly on the body and expel waste products at a similar rate. The testosterone ester has the shortest half-life of all testosterone esters, at 4 days, thanks to its three-carbon chain.
References
1.Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 2005;280:19496-506.
2.Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2014 Jun.
3.Barnes KM, Dickstein B, Cutler GB Jr, et al. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996;35:4820-7.
4.Aveed (testosterone undecanoate Injection) package insert. Malvern, PA: Endo Pharmaceuticals Solutions Inc.; 2014 Mar.
5.DELATESTRYL (Testosterone Enanthate Injection, USP) package insert. Lexington, MA: Indevus Pharmaceuticals, Inc.; 2007 July.
6.Axiron (testosterone) topical solution, package insert. Indianapolis, IN: Lilly USA, LLC; 2011 Dec.
7.The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
8.Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
9.WD Finkle, S Greenland, GK Ridgeway, et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. DOI: 10.1371/journal.pone.0085805
10.FDA Medwatch – FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Retrieved January 31, 2014. Available on the World Wide Web http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm
11.Natesto (testosterone) nasal gel package insert. Durants, Christ Church Barbados: Trimel BioPharma SRL; 2014 May.
12.Testim (testosterone gel) package insert. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2010 Apr.
13.Androgel (testosterone gel) package insert. Marietta, GA: Solvay Pharmaceuticals, Inc.; 2012 Sept.
14.Striant (testosterone buccal system) package insert. Livingston, NJ: Columbia Laboratories, Inc.; 2014 Mar.
15.Fortesta (testosterone) gel, package insert. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010 Dec.
16.DEPO-TESTOSTERONE (testosterone cypionate) injection, package insert. New York, NY: Pharmacia & Upjohn Co.; 2006 Sept.
17.Kochenour NK. Lactation suppression. Clin Obstet Gynecol. 1980;23:1045-1059.
18.Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 2005;280:19496—506.
19.Barnes KM, Dickstein B, Cutler GB Jr, et al. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996;35:4820—7.
20.Wells PS, Holbrook AM, Crowther NR et al. Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676—83.
21.Goffin E, Pirson Y, Geubel A, et al. Cyclosporine-methyltestosterone interaction. Nephron 1991;59:174—5.
22.Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, et al. Possible cyclosporin-danazol interaction in a patient with aplastic anaemia. Am J Hematol 1999;62:63—4.
23.Moller BB, Ekelund B. Toxicity of cyclosporine during treatment with androgens. N Engl J Med 1985;313:1416.
24.Ross WB, Roberts D, Griffin PJ, et al. Cyclosporin interaction with danazol and norethisterone. Lancet 1986;1:330.
25.Androgel® (testosterone gel) package insert. Montrogue, France: Laboratories Besins International; 2005 Aug.
26.Zoladex® (goserelin acetate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2003 Dec.
27.Viadur® (leuprolide implant) package insert. Westhaven, CT: Bayer Pharmaceuticals; 2002 May.
28.Humatrope™ (somatropin);package insert. Indianapolis, IN: Eli Lilly and Company; 2003 Jul.
29.Androderm® (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 1999 Jan.
30.Propecia® (finasteride) package insert. Whitehouse Station, NJ: Merck & Co., INC.; 2003 Oct.
31.Avodart™ (dutasteride) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005 May.
32.Robbers JE, Tyler VE. Tyler’s Herbs of Choice: the Therapeutic Use of Phytomedicinals. Binghamton NY: Haworth Herbal Press, Inc.; 1999.
33.German Commission E. Saw Palmetto berry, Sabal fructus, monograph Published March 2, 1989 and revised January 17, 1991. In: Blumenthal, M et al ., eds. The complete German Commission E Monographs -Therapeutic Guide to Alternative Medicines. Bosto
34.Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12:S327—33.
35.Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
36.Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male 2003;6:1—7.
37.Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity, and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Clin Endocrinol 2006; 154:899—90
38.Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab 1996; 81:1582—5.
39.Corrales JJ, Burgo RM, Garcia-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53:666—72
40.Lee CH, Kuo SW, Hung YJ, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Res 2005;31:139—148.
41.Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987;64:960—3.
42.Aldercreutz H, Mazur W. Phyto-estrogens and western diseases. Annals of Medicine 1997;29:95—120.
43.Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2013 Dec.
44.Letairis™ (ambrisentan) package insert. Foster City, CA: Gilead Sciences, Inc; 2008 Oct.
45.Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015 Jan.
46.Gilotrif (afatinib) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2013 Nov.
47.Androgel 1.62% (testosterone gel) package insert. North Chicago, IL: Abbott Laboratories; 2014 Nov.
48.Naik BS, Shetty N, Maben EVS. Drug-induced taste disorders. European Journal of Internal Medicine 2010; 21:240-243.
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.